FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19 | FDA
FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19
Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution
A nasal spray prevented 80% of Covid infections; ~300,000 people in China have received SA55, a broad spectrum monoclonal antibody
Comprehensive method for producing high-affinity mouse monoclonal antibodies of various isotypes against (4-hydroxy-3-nitrophenyl)acetyl (NP) hapten
New protocol from Japan enables high-affinity monoclonal antibody production from single B cells in 6 days.
Cost-effective and works across antibody types, including for SARS-CoV-2 spike protein.
A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification
Next generation medicines in fight against Covid:
Focusing specifically on the receptor-binding domain (RBD) rather than the entire SARS-CoV-2 spike protein provides enhanced, long-lasting protection against viral mutations